PSMA-1-DOTA
PSMA-1-DOTA is a prostate-specific membrane antigen (PSMA) binder with high affinity, enables targeted radionuclide delivery for imaging and therapy. PSMA-1-DOTA acts as a tumor growth inhibitor that reduces growth of PSMA-expressing prostate cancer tumors.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3024672-17-8
- Fòrmula: C62H100N14O27
- Peso molecular:1473.54
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
In Vivo
[177Lu]Lu-PSMA-1-DOTA (111 MBq total, 4 doses of 27.75 MBq over 2 days; 111 MBq single dose; i.v.) effectively inhibits tumor growth in PC3pip xenograft mice for 24 days[1].
[68Ga]Ga-PSMA-1-DOTA (7.4 MBq; i.v.) targets PC3pip tumors with minimal non-target uptake in kidneys and salivary glands in xenograft mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:athymic nude [Foxn1/nu/Foxn1/nu] (male, 6-8 weeks old, PC3pip subcutaneous xenograft model)[1]
-
Dosage:111 MBq (3 mCi) total, 4 doses of 27.75 MBq each over 2 days; 111 MBq (3 mCi) single dose
-
Administration:i.v.; 4 doses over 2 days (day 0); single dose (day 13)
-
Result:Eliminated tumor growth for 24 days; achieved tumor inhibitory activity comparable to [¹⁷⁷Lu]Lu-PSMA-617 (positive control).
-
Animal Model:athymic nude [Foxn1/nu/Foxn1/nu] (male, PC3pip subcutaneous xenograft model)[1]
-
Dosage:7.4 MBq (200 μCi)
-
Administration:i.v.
-
Result:Showed significantly lower kidney and salivary gland uptake compared to [⁶⁸Ga]Ga-PSMA-11 and [⁶⁸Ga]Ga-PSMA I&T; reached tumor-to-left salivary gland ratio of 13.45 at 30 minutes and 27.43 at 1 hour post-injection.
-
Animal Model:NMRI (male, 8 weeks old)[1]
-
Dosage:1.4 mg/kg
-
Administration:i.v.; single dose
-
Result:Observed no mortality, significant body weight changes, or abnormal clinical signs; detected no significant changes in clinical chemistry parameters on day 2 or day 15; identified test item-related histopathological changes in spleen, bone marrow, and inguinal lymph nodes (present after 14-day recovery).
Chemical Information
-
No. CAS 3024672-17-8
-
Peso molecular 1473.54
-
Fòrmula C62H100N14O27
-
SMILES
OC(CN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CCN1CC(NCCCC[C@@H](C(N)=O)NC([C@@H](CCC(O)=O)NC([C@@H](CCC(O)=O)NC([C@@H](CCC(O)=O)NC(CCCCCNC(C2CCC(CC2)CNC(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PSMA-1-DOTA Related Classifications
HY-185167 Related Classifications
Powered by Bioz